Effects of arecoline on proliferation of oral squamous cell carcinoma cells by dysregulating c-Myc and miR-22, directly targeting oncostatin M
Fig 2
The effects of arecoline on c-Myc expression and transcriptional activity.
ORL-48(T) cells treated with 0, 0.025 and 25 μg/ml of arecoline for 24 hours were assayed to determine levels of c-Myc expression in mRNA (RT-PCR) (A) and protein (western blot) (B). Relative c-Myc expression and relative intensity of c-Myc protein band were investigated in RT-PCR and western blot result (C-D). Statistical significance of the differences was analyzed using One-way ANOVA followed by Tukey’s multiple comparison test (*P < 0.05, **P < 0.01 and ***P < 0.001). Mock or pGL3-cMYCP vector-untransfected or transfected ORL-48(T) cells were treated with 0, 0.025, 0.25 and 25 μg/ml of arecoline for 24 and 48 hours (E). The transcriptional activity of the c-myc promoter was determined by luciferase activity. Statistical significance of the differences of luciferase activity was analyzed using Two-way ANOVA (*P < 0.05, **P < 0.01 and ***P < 0.001).